Trials / Completed
CompletedNCT02057692
Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
The Evaluation of the Intestinal Bile Acid Transport (IBAT) Inhibitor LUM001 in the Reduction of Pruritus in Alagille Syndrome, a Cholestatic Liver Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Mirum Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 12 Months – 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is a randomized, double-blind, placebo-controlled study in children with Alagille Syndrome (ALGS). The study will investigate the effects of LUM001, compared to placebo, on pruritus, serum bile acids, liver enzymes, and other biochemical markers in patients with ALGS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LUM001 | LUM001 administered orally |
| DRUG | Placebo | Placebo administered orally |
Timeline
- Start date
- 2014-11-24
- Primary completion
- 2016-11-16
- Completion
- 2016-11-16
- First posted
- 2014-02-07
- Last updated
- 2019-03-26
- Results posted
- 2018-01-23
Locations
13 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02057692. Inclusion in this directory is not an endorsement.